Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland

Blood (2024) 144 (Supplement 1): 5998.

https://doi.org/10.1182/blood-2024-204046

Published: 2024

Journal Articles

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C. Schuh

Blood (2018) 131 (26): 2906–2914.

https://doi.org/10.1182/blood-2017-09-804658

Published: 2018

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Anthony Selwyn Stein, MD, Max S. Topp, MD, Hagop M Kantarjian, MD, Nicola Goekbuget, MD, Ralf C Bargou, MD, Mark R Litzow, MD, Alessandro Rambaldi, MD, Josep Ribera, MD PhD, Alicia Zhang, PhD, Zachary Zimmerman, MD PhD, Stephen J. Forman, MD

Blood (2015) 126 (23): 861.

https://doi.org/10.1182/blood.V126.23.861.861

Published: 2015

Journal Articles

Transplanted Donor APC Co-Stimulatory Molecule Expression Is Required To Elicit Host T Cell Resistance in MHC-Matched Allogeneic BMT Recipients Following Reduced Intensity Conditioning.

Monica Jones, Bruce Blazar, MD, Zachary Zimmerman, PhD, Robert B. Levy, PhD

Blood (2006) 108 (11): 620.

https://doi.org/10.1182/blood.V108.11.620.620

Published: 2006

NARROW

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Transplanted Donor APC Co-Stimulatory Molecule Expression Is Required To Elicit Host T Cell Resistance in MHC-Matched Allogeneic BMT Recipients Following Reduced Intensity Conditioning.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Transplanted Donor APC Co-Stimulatory Molecule Expression Is Required To Elicit Host T Cell Resistance in MHC-Matched Allogeneic BMT Recipients Following Reduced Intensity Conditioning.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only